Head-to-Head trial: which drug better protects joints from arthritis damage?
NCT ID NCT07486843
Summary
This study compares two common treatments for early psoriatic arthritis to see which one is better at preventing permanent joint damage. It will enroll 108 adults who have had symptoms for two years or less and have not yet tried these specific medications. Researchers will use detailed 3D hand scans to measure changes in bone erosion over 48 weeks in people taking either methotrexate or a TNF inhibitor (adalimumab).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS (PSA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Chinese University of Hong Kong, Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.